Predicting Compound Selectivity by Self‐Organizing Maps: Cross‐Activities of Metabotropic Glutamate Receptor Antagonists

The self-organizing map (SOM) principle was introduced by Kohonen in 1982, and has been applied to a variety of tasks in chemistry and chemical biology ever since. In this study, we used the SOM algorithm for mapping known ligands according to a topological pharmacophore descriptor (CATS) and predicting potential cross-activities. Our aim was to see whether 1) the descriptor is able to discriminate antagonists of metabotropic glutamate receptors (mGluR) 1 and 5, and 2) the SOM could be used for predicting potential additional binding behaviors of the ligands. First, an mGluR reference collection containing 338 compounds was compiled including published and Merz in-house structures of noncompetitive group I mGluR antagonists. The collection comprises two subsets: allosteric mGlu1 receptor antagonists (213 compounds), and allosteric mGlu5 receptor antagonists (125 compounds). These molecules cover a broad range of binding activities (Ki values between 1 nm and 10 mm) and represent different chemical classes. This mGluR reference library was complemented by the molecules from the COBRA database (v. 3.12; 5376 molecules) containing a broad set of known drugs, leads, and lead candidates affecting a large number of different drug targets. Subsequently, the molecules were converted to a vector representation giving the scaled occurrence frequencies of topological potential pharmacophore point pairs (CATS2D method). 7] In this study, intramolecular distances from zero to nine bonds were considered, resulting in a 150-dimensional vector representation of each molecular compound. The complete COBRA database was subjected to clustering and mapping onto a two-dimensional grid by the SOM approach. The SOM provides a nonlinear two-dimensional projection of the 150-dimensional data space (“chemical space”), where local neighborhood is conserved. This means, that molecules that are located close to each other on the map are also close in the original high-dimensional space. For SOM training we applied a slightly modified version of the Kohonen algorithm as described previously. 8] As a result, all molecules from COBRA were distributed into 225 (15A15) clusters ACHTUNGTRENNUNG(“neurons”

[1]  Burton S. Rosner,et al.  Neuropharmacology , 1958, Nature.

[2]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[3]  T. Kohonen Self-organized formation of topographically correct feature maps , 1982 .

[4]  T. Biden,et al.  Structural subtypes of the dopamine D2 receptor are functionally distinct: expression of the cloned D2A and D2B subtypes in a heterologous cell line. , 1992, Molecular Endocrinology.

[5]  M. Martres,et al.  Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. , 1992, European journal of pharmacology.

[6]  Johann Gasteiger,et al.  The comparison of geometric and electronic properties of molecular surfaces by neural networks: Application to the analysis of corticosteroid-binding globulin activity of steroids , 1996, J. Comput. Aided Mol. Des..

[7]  R. Leurs,et al.  Regulation of the human histamine H1 receptor stably expressed in Chinese hamster ovary cells , 1996, British journal of pharmacology.

[8]  G Schneider,et al.  Artificial neural networks for computer-based molecular design. , 1998, Progress in biophysics and molecular biology.

[9]  Schmid,et al.  "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening. , 1999, Angewandte Chemie.

[10]  Johann Gasteiger,et al.  Neural networks in chemistry and drug design , 1999 .

[11]  Roland Heckendorn,et al.  2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist , 1999, Neuropharmacology.

[12]  Gisbert Schneider,et al.  „Grundgerüstwechsel”︁ (Scaffold‐Hopping) durch topologische Pharmakophorsuche: ein Beitrag zum virtuellen Screening , 1999 .

[13]  Jaroslaw Polanski,et al.  The Comparative Molecular Surface Analysis (COMSA): A Novel Tool for Molecular Design , 2000, Comput. Chem..

[14]  Mark Washburn,et al.  3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. , 2003, Journal of medicinal chemistry.

[15]  Petra Schneider,et al.  Comparison of correlation vector methods for ligand-based similarity searching , 2003, J. Comput. Aided Mol. Des..

[16]  Gisbert Schneider,et al.  Collection of bioactive reference compounds for focused library design , 2003 .

[17]  Gisbert Schneider,et al.  Ligand-based combinatorial design of selective purinergic receptor (A2A) antagonists using self-organizing maps. , 2003, Journal of combinatorial chemistry.

[18]  Johann Gasteiger,et al.  Mining High-Throughput Screening Data of Combinatorial Libraries: Development of a Filter to Distinguish Hits from Nonhits , 2004, J. Chem. Inf. Model..

[19]  Teuvo Kohonen,et al.  Self-organized formation of topologically correct feature maps , 2004, Biological Cybernetics.

[20]  Ersin Bayram,et al.  Supervised Self-Organizing Maps in Drug Discovery. 1. Robust Behavior with Overdetermined Data Sets , 2005, J. Chem. Inf. Model..

[21]  Gisbert Schneider,et al.  Navigation in Chemical Space: Ligand‐Based Design of Focused Compound Libraries , 2005 .

[22]  Chemogenomics in Drug Discovery. A Medicinal Chemistry Perspective. Vol. 22 in Methods and Principles in Medicinal Chemistry Edited by H. Kubinyi and G. Muller (Axxima Pharmaceuticals). Wiley-VCH, Weinheim. 2004. xxiv + 463 pp. 17 × 24.5 cm. $180.00. ISBN 3-527-30987-X. , 2005 .

[23]  R. Wouters,et al.  Synthesis, structure-activity relationship, and receptor pharmacology of a new series of quinoline derivatives acting as selective, noncompetitive mGlu1 antagonists. , 2005, Journal of medicinal chemistry.

[24]  H Kubinyi,et al.  Chemogenomics in drug discovery. , 2006, Ernst Schering Research Foundation workshop.

[25]  Tobias Noeske,et al.  Allosteric Modulation of Family 3 GPCRs , 2006 .